Estrogen compositions for vaginal administration
View Patent ↗Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.
1. A pharmaceutical composition for vaginal administration consisting of:
(a) at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition;
(b) at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid; and
(c) at least one gelation promoter selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to gel said polymer and to substantially solubilize the estrogen,
wherein at least 50% of the estrogen is dissolved in said composition at 15° C., and
wherein said composition is substantially free of ethanol.
2. The pharmaceutical composition of claim 1 , wherein the at least one estrogen is 17β-estradiol.
3. The pharmaceutical composition of claim 1 , wherein the amount of the at least one estrogen is from about 0.0005% to about 0.05% by weight of the composition.
4. The pharmaceutical composition of claim 3 , wherein the amount of the at least one estrogen is from about 0.00075% to about 0.025% by weight of the composition.
5. The pharmaceutical composition of claim 1 , wherein the at least one hydrogen-bonding gelation polymer is present in an amount sufficient to form a gel with a viscosity ranging from about 50 Pa·s to about 1000 Pa·s at 20° C.
6. A pharmaceutical composition for vaginal administration consisting of:
(a) at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition;
(b) at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid;
(c) at least one gelation promoter selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to gel said polymer and to substantially solubilize the estrogen; and
(d) water,
wherein at least 50% of the estrogen is dissolved in said composition at 15° C., and
wherein said composition is substantially free of ethanol.
7. The pharmaceutical composition of claim 1 , wherein the polyhydric alcohol is selected from the group consisting of 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, butynediol, butenediol, diethylene glycol, ethylene glycol, glycerol, glycofurol, 1,2-hexanediol, 1,2,6-hexanetriol, 3-methyl-1,5-pentanediol, 2-methyl-1,3-propanediol, 1,9-nonanediol, 1,5-pentanediol, poly(vinyl alcohol), 1,3-propanediol, propylene glycol and combinations thereof.
8. The pharmaceutical composition of claim 1 , wherein the polyglycol is selected from the group consisting of butyl glycol, butyl diglycol, butyl polyglycol, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol diethyl ether, dipropylene glycol, dipropylene glycol dimethyl ether, poloxamers, methyl diglycol, methyl triglycol, methyl tetraglycol, poly(ethylene glycol), poly(oxyethylene) alkyl ethers, poly(oxyethylene) alkyl esters, poly(propylene glycol), tetraethylene glycol dimethyl ether, triethylene glycol, triethyl glycol dimethyl ether, tripropylene glycol, glycol-silane copolymers and combinations thereof.
9. The pharmaceutical composition of claim 1 , wherein the polyglycol is selected from the group consisting of polyoxyethylene, polyoxypropylene, a copolymer of polyoxyethylene and polyoxypropylene and combinations thereof.
10. The pharmaceutical composition of claim 1 , wherein at least 60% of the estrogen is dissolved in said composition at 15° C.
11. The pharmaceutical composition of claim 10 , wherein at least 90% of the estrogen is dissolved in said composition at 15° C.
12. A method of making a pharmaceutical composition for vaginal administration consisting of the step of admixing at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition, at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid, and at least one gelation promoter, the gelation promoter being selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to substantially solubilize the estrogen and to gel the polymer to form the pharmaceutical composition, wherein at least 50% of the estrogen is dissolved in the composition at 15° C., and wherein said composition is substantially free of ethanol.
13. The method of claim 12 , wherein the admixing step consists of (a) substantially solubilizing the estrogen in the gelation promoter or in an aqueous solution thereof to form a substantially solubilized estrogen preparation and (b) combining the substantially solubilized estrogen preparation with the hydrogen-bonding gelation polymer to form the pharmaceutical composition.
14. A pharmaceutical composition made by the step of admixing at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition, at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid, and at least one gelation promoter, the gelation promoter being selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to substantially solubilize the estrogen and to gel the polymer to form the pharmaceutical composition, wherein at least 50% of the estrogen is dissolved in the composition at 15° C., wherein said composition is substantially free of ethanol, and wherein said composition is free of conventional neutralizers to achieve gelation, wherein said conventional neutralizers are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, aminomethyl propanol, tetrahydroxypropyl ethylenediamine, triethanolamine, tromethamine, PEG-15 cocamine, diisopropanolamine, and triisopropanolamine, wherein said composition is free of buffers, and wherein the admixing step consists of (a) substantially solubilizing the estrogen in the gelation promoter or in an aqueous solution thereof to form a substantially solubilized estrogen preparation and (b) combining the substantially solubilized estrogen preparation with the hydrogen-bonding gelation polymer to form the pharmaceutical composition.
15. A method of vaginal administration of estrogen for a female comprising the step of administering the pharmaceutical composition of claim 1 to the vaginal epithelial tissue of the female.
16. A pharmaceutical composition for vaginal administration consisting of:
(a) 17β-estradiol in an amount of about 0.0005% to about 0.05% by weight of the composition;
(b) at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid;
(c) at least one gelation promoter selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof; and
(d) water, and
wherein the gelation promoter is in an amount effective to gel the polymer and to substantially solubilize the 17β-estradiol so that at least 50% of the 17β-estradiol is dissolved in the composition at 15° C.; and gelling of the polymer is caused by hydrogen-bonding with functional groups of the gelation promoter.
17. The pharmaceutical composition of claim 16 , wherein the gelation promoter is polyethylene glycol.
18. The pharmaceutical composition of claim 16 , wherein the gelation promoter is propylene glycol.
19. The pharmaceutical composition of claim 16 , wherein the gelation promoter is a combination of polyethylene glycol and propylene glycol.
20. The pharmaceutical composition of claim 16 , wherein the at least one hydrogen-bonding gelation polymer is present in an amount sufficient to form a gel with a viscosity ranging from about 50 Pa·s to about 1000 Pa·s at 20° C.
21. A pharmaceutical composition for vaginal administration consisting of:
(a) at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition;
(b) at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid;
(c) at least one gelation promoter selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to gel said polymer and to substantially solubilize the estrogen; and
(d) at least one preservative,
wherein at least 50% of the estrogen is dissolved in said composition at 15° C., and
wherein said composition is substantially free of ethanol.
22. A pharmaceutical composition for vaginal administration consisting of:
(a) at least one estrogen selected from 17β-estradiol or salt thereof in an amount of about 0.00001% to about 2% by weight of the composition;
(b) at least one hydrogen-bonding gelation polymer that is a homopolymer, copolymer or interpolymer of acrylic acid; and
(c) at least one gelation promoter selected from the group consisting of polyhydric alcohols, polyglycols and combinations thereof in an amount effective to gel said polymer and to substantially solubilize the estrogen,
wherein at least 50% of the estrogen is dissolved in said composition at 15° C.,
wherein said composition is substantially free of ethanol,
wherein said composition is free of conventional neutralizers and buffers that increase the pH to achieve gelation, and
wherein said conventional neutralizers are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, aminomethyl propanol, tetrahydroxypropyl ethylenediamine, triethanolamine, tromethamine, PEG-15 cocamine, diisopropanolamine, and triisopropanolamine.